Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-20Expression of the Genome in Lymphoid Malignancies
-
CLINICAL_TRIALS study record update · 2026-04-20Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study
-
CLINICAL_TRIALS study record update · 2026-04-20Exploratory Study Evaluating the Relevance of [68Ga]Ga -PentixaFor for Initial Staging and Therapeutic Evaluation of Symptomatic Multiple Myeloma Patients in First Line Treatment or in Relapse
-
CLINICAL_TRIALS study record update · 2026-04-16A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)
-
CLINICAL_TRIALS study record update · 2026-04-16Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-16ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
-
CLINICAL_TRIALS study record update · 2026-04-16An Open-label, Multi-center Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-16Pre-malignant States to Hematologic Malignancies in Firefighters
-
CLINICAL_TRIALS study record update · 2026-04-16Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
-
CLINICAL_TRIALS study record update · 2026-04-16A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
-
CLINICAL_TRIALS study record update · 2026-04-16A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-B-Cell Maturation Antigen (BCMA) Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-16Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-15Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-15Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
-
CLINICAL_TRIALS study record update · 2026-04-15Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-15Voice as a Digital Biomarker of Neurotoxicity in CAR T-Cell Therapy
-
CLINICAL_TRIALS study record update · 2026-04-14A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-14Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
-
CLINICAL_TRIALS study record update · 2026-04-14Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
-
CLINICAL_TRIALS study record update · 2026-04-14A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-14A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-14An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
-
CLINICAL_TRIALS study record update · 2026-04-13Remote Monitoring With Health-Coaching for Lifestyle Changes in Older Patients With Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2026-04-13The Prospective Collection, Storage and Reporting of Data on Patients